This study investigated the early effects of the new kidney allocation system (KAS) on the access of prior living kidney donors (PLDs) to deceased donor kidney transplants. Using data from the Organ Procurement and Transplantation Network, we compared prevalent and incident cohorts of PLDs in the 1-year periods before and after KAS implementation (pre-KAS group: December 4, 2013, to December 3, 2014, n = 50 [newly listed PLDs]; post-KAS group: December 4, 2014, to December 3, 2015, n = 39). We assessed transplant rates per active patient-year, waiting times, and Kidney Donor Profile Index (KDPI) of transplanted kidneys. Transplant rates were not statistically different before and after KAS implementation for either prevalent (2.37 vs. 2.29, relative risk [RR] 0.96; 95% confidence interval [CI] 0.62-1.49) or incident (4.76 vs. 4.36, RR 0.92; 95% CI 0.53-1.60) candidates. Median waiting time (MWT) to deceased donor kidney transplant for prevalent PLDs in the post-KAS cohort was 102.6 days compared with 82.3 days in the pre-KAS cohort (p = 0.98). The median KDPI for PLD recipients was 31% with KAS versus 23% before KAS (p = 0.02). Despite a sharp decrease in the MWT for highly prioritized candidates with calculated panel reactive antibodies of 98-100% (from >7000 to 1164 days), PLDs still had much shorter waiting times (MWT 102.6 days). The new system continues to provide quick access to high-quality organs for PLDs.
Introduction
Living kidney donation is generally considered to be safe, and end-stage renal disease is relatively rare among kidney donors (1, 2) , but the number of prior living donors (PLDs) who have needed kidney transplant is not negligible. About 40-50 PLDs are added to the Organ Procurement and Transplantation Network (OPTN) kidney waiting list each year ( Figure 1) , with a total of 486 PLDs ever waiting between September 1996 and December 2015. The new kidney allocation system (KAS) instituted in December 2014 changed the position of PLDs in the allocation sequence. The primary goal of KAS was to change the nation's system for allocating deceased donor kidneys from a system based largely on waiting time to one that makes better use of a scarce national resource and improves equity in access for disadvantaged groups of candidates. KAS operationalized these goals by improving longevity matching between recipients and their transplanted kidneys, increasing priority for very highly sensitized patients, changing the waiting time calculation to include time spent on maintenance dialysis prior to waitlisting, and expanding opportunities for blood type B candidates ( Figure 2 ).
In developing these changes, the transplant community carefully considered the effects that KAS could have on other special populations such as pediatric patients and PLDs. Consequently, KAS maintained high priority for these groups (3) (4) (5) . As shown in Figure 2 , PLDs receive local priority for kidneys with a Kidney Donor Profile Index (KDPI) ≤85%. However, candidates with calculated panel reactive antibodies (CPRA) of 98-100% now receive higher priority than PLDs, and some 0 ABDRmismatch offers continue to receive higher priority. PLDs, however, continue to receive priority over pediatric candidates and all other local adults.
PLDs began to receive high priority in the OPTN's kidney allocation policy in September 1996. PLDs were given local priority over all kidney-alone candidates except for 0 ABDR-mismatch offers for non-extended criteria donor kidneys ( Figure 2 ). To receive kidney offers through PLD priority, a PLD's transplant program must submit a request to the United Network for Organ Sharing Organ Center, which processes these requests within one business day.
Appropriate access to transplantation for PLDs has focused primarily on candidates' waiting time to deceased donor transplantation, but the quality of the organs offered to PLD candidates is also important. Historically, PLDs on the waiting list have received high-quality organs (6) and assessing continued access to high-quality, low-KDPI organs is essential to evaluate the effects of KAS on PLD access to transplantation. We investigated the impact of KAS on PLDs' access to deceased donor kidneys and the relative quality of the organs that PLDs receive.
Materials and Methods
This study used data from OPTN. The OPTN data system includes data on all donors, waitlisted candidates, and transplant recipients in the United States, submitted by the members of the OPTN, and has been described elsewhere (https://optn.transplant.hrsa.gov/data/about-data/). The Health Resources and Services Administration (HRSA), U.S. Department of Health and Human Services, oversees the activities of the OPTN contractor. Dialysis dates were supplemented with data from CMS Form 2728.
This retrospective observational study compared data from 1 year before KAS (December 4, 2013, to December 3, 2014) with data from the subsequent year (December 4, 2014, to December 3, 2015) . Institutional review board exemption was obtained from HRSA.
Unlike previous research (1) that limited their PLD cohorts to those who donated after 1994, our cohort included all PLDs who were on the OPTN kidney waiting list and who received PLD priority during the study period, regardless of when they donated. This accounts for the larger number of PLDs found on the waiting list in this study. We analyzed both prevalent (ever waiting during the study period) and incident (added to the waiting list during the study period) cohorts, and we used the unit of analysis (registration vs. patient) most appropriate for each analysis. For comparison with PLDs, we also analyzed the following subpopulations of kidney candidates: pediatric patients, CPRA 98-100% adults, and CPRA 0-97% adults. Results include only deceased donor, kidney-alone transplants.
The KDRI (7) was calculated using donor factors and converted to KDPI using a reference population of all deceased kidney donors recovered for transplantation in 2014 (8) . KDPI ranges from 0 to 100, with lower numbers associated with kidneys expected to last longer. For descriptive analyses, we used the PLD's CPRA on record 28 days after listing (or at removal for patients removed prior to 28 days). For other analyses, we accounted for changes in patient CPRA while on the waiting list. Candidates aged <18 years at time of listing were considered pediatric.
We compared the deceased donor transplant rate per patient-year (patient level), Kaplan-Meier median waiting time (registration level), and median KDPI of transplanted kidneys (registration level) for PLDs before and after KAS implementation. Transplant rates were calculated by dividing the number of deceased donor kidney-alone transplants by the number of active years that the patients waited during each era. Relative risk (RR) was approximated as the ratio of post-versus pre-KAS transplant rates with 95% confidence limits calculated using the method described by Mantel and Haenszel (9).
We used Cox proportional hazards models to assess the impact of KAS on time to deceased donor transplant for four patient strata (PLDs, pediatric patients, CPRA 0-97% adults, and CPRA 98-100% adults), without additional covariates. Prevalent cohorts were used to increase sample sizes and statistical power and to allow estimation of time-to-transplant curves that yield median waiting times (MWTs). Counting process data structure was used to accommodate left truncation and to model CPRA changes and pre-versus post-KAS periods as time-dependent strata (10) . For PLDs, we compared results using two timescales: (i) all time spent on the waiting list (usual chronological time) and (ii) only time waiting in active status with PLD priority. Risk-adjusted Cox modeling was done but is not shown because all factors were statistically insignificant (including KAS effect), possibly an artifact of the small total sample size.
Pre-versus post-KAS hypothesis tests were performed using the score test with pre-and post-KAS periods as a covariate in a Cox model; this test is equivalent to the log-rank test (10) . Renyi tests (11) were also evaluated on incident PLD cohorts because of potential violations of the proportional hazards assumption. Analyses wereperformed using SAS/STAT version 12.1 (SAS Institute, Inc., Cary, NC). (Figure 4 ). The p-value for the Renyi log-rank statistic (11), which does not rely on the proportional hazards assumption, was 0.24. The post-KAS MWT for PLDs compares favorably with pediatric kidney-alone candidates (MWT 599.4 days) and CPRA 98-100% adult kidney-alone candidates (MWT 1164.3 days), despite the dramatic reduction in MWT for this latter group (from >7000 days) (Figure 4 ) in the post-KAS era.
In the prevalent post-KAS cohort (n = 81), 45 PLDs waited >180 days, and some of those had spent substantial time waiting before KAS. Figure 5 illustrates possible explanatory factors for these longer waits. These recipients included 11 PLDs who had CPRA ≥80%, 23 PLDs who had waited ≤90 days in active status, and six PLDs who experienced a delay in receiving PLD priority (12) . In addition, one PLD had CPRA 37%, another received a living donor transplant after spending substantial time waiting in inactive status, one was too well for transplant, and three PLDs spent a large proportion of their long waiting times in inactive status. When considering only time spent in active status with PLD priority, post-KAS MWT for prevalent PLDs was 51.6 days (range 3-762 days ) (Figure 6 ), which was not statistically different (p = 0.36) from the pre-KAS MWT of 20.3 days (range 2-409 days).
The median KDPI for prevalent PLDs in the post-KAS cohort who were transplanted within 1 year after KAS was 31% (range 5-85%) compared with 23% (range 1-82%) in the pre-KAS cohort (p = 0.02; Figure 7) ; this difference was not explained by CPRA differences between the two cohorts. For incident PLDs transplanted in the 1-year post-KAS time period, the median KDPI was 21% (range 5-85%), compared with 18% (range 4-53%) for PLDs added and transplanted before KAS (p = 0.19). Transplanted PLDs in both incident cohorts had very low CPRA (median 0% for both cohorts; 71.0% of PLDs transplanted before KAS vs. 85.7% after KAS had CPRA 0%). These KDPIs compared favorably with those of organs accepted for post-KAS prevalent cohorts of 98-100% CPRA adults (median 36%, range 0-98%) (Figure 7) and 0-97% CPRA adults (median 47%, range 0-100%). In comparison, median KDPI of kidneys transplanted into pediatric candidates during this time period was 13%. Notably, 20 of 21 kidneys (95.2%) accepted 
Discussion
This study demonstrates that, despite substantial changes in the kidney allocation sequence, PLDs continue to be transplanted rapidly. The transplant rate for post-KAS PLDs remains higher than that of any other patient subgroup, and this study did not identify a statistically significant change in PLDs' access to transplantation. The observed increase in MWT was neither statistically nor clinically significant, whether including all patient waiting time or only time in active status with PLD priority.
It is conceivable that MWT for PLDs increased slightly after KAS implementation because of the allocation change that placed very highly sensitized candidates at the top of the list. However, the statistical power to detect such a difference is low, given the sample sizes afforded by this relatively small subpopulation of kidney candidates. The time-to-transplant distributions may also differ in ways that may not be detected by tests relying on the proportional hazards assumption. Statistical uncertainty remains, but practically speaking, PLDs' access to transplant has changed little with KAS, and these patients continue to receive kidney transplants quickly. Furthermore, PLDs have maintained a marked MWT advantage relative to other kidney candidates, including those with CPRA 98-100% (Figure 4 ). These findings illustrate the success of KAS in maintaining PLDs' rapid access to kidney transplants. A comparison of post-KAS waiting times for PLDs and other patients showed that PLDs are still effectively at the top of the list, having by far the shortest waiting times of any kidney-alone candidate subpopulation. This real-world metric is more important to PLDs' experience than their position in the allocation sequence prescribed by KAS (Figure 2 ). This finding is entirely plausible because although very highly sensitized patients now appear ahead of PLDs, they are by definition incompatible with most donors and are screened off of many match runs. In fact, we found that 40% of the time, no candidates appear on the match run ahead of PLDs, with a median of just one candidate (mean of three) ahead of PLDs.
Although PLDs are not first in the KAS allocation sequence, they are effectively at the top of the list under KAS, as demonstrated by very short waiting times. Being literally first in the allocation sequence would mean superseding extremely difficult-to-match candidates now being helped by KAS and also moving ahead of multiorgan kidney candidates (e.g. heart-kidney, liver-kidney) who currently take precedence over kidney-alone candidates.
The impact of such a change on PLDs' already short MWT would likely be small, and any potential positive impact on public perception must be weighed against the very real likelihood of a PLD depriving a CPRA 100% patient of their only chance of a compatible transplant.
Although evaluating the entire wait experienced by PLDs on the waiting list is critical in this assessment, it is also insightful to measure an allocation system's performance after eliminating factors that are outside of the system's control, such as delays in PLDs being placed in active status (which is necessary to receive organ offers) and receiving PLD priority (which affects the likelihood of receiving an offer). Our finding of a post-KAS MWT of just 51.6 days once a PLD was set to active status with PLD priority further suggests that the allocation system continues to perform as desired for PLDs. The fact that MWT dropped by half for patients in active status with PLD priority suggests that modifiable factors play an important role in determining access (12) . Particularly important is the issue of preemptive listing, which occurred for only 48.7% of post-KAS listings. PLDs should be aware that they may be listed and receive a transplant before needing dialysis, and closer monitoring of their health after donation may facilitate this.
There was a statistically significant increase in the KDPI of kidneys received by PLDs ever waiting in the year after KAS implementation. The kidneys received by PLDs, however, still compare favorably with those received by most kidney candidates in that time period. Of note, 95.2% of kidneys received by PLDs in the post-KAS cohort were within the range of KDPIs transplanted into pediatric kidney-alone candidates (1-73%) during the same time period, suggesting that PLDs generally are receiving and accepting high-quality organ offers.
The higher median KDPI (31% vs. 23%) of organs received by PLDs is likely explained, at least in part, by the fact that PLDs now have prioritized access to a broader pool of kidneys (KDPI ≤85%) compared with the pre-KAS group (non-extended criteria donors) (Figure 2 ). That CPRA 98-100% recipients have disproportionately received lower KDPI transplants is also likely a contributing factor (13) . The 3-year estimated graft survival rate for a KDPI 30% kidney (85.6%) differs little from a KDPI 20% kidney (86.8%) (8) , suggesting that this slight increase in KDPI for PLD recipients will have little clinical impact.
This analysis represents an early assessment of PLDs' access to deceased donor kidney transplantation following the implementation of KAS. Continued assessment of waiting list outcomes for PLDs to ensure that their transplant access does not decrease unexpectedly is essential. KAS so far appears to have resulted in the expected "bolus" effect of many highly sensitized kidney candidates receiving transplants during the first year after KAS implementation (13) ; as this effect lessens and as the "backlog" of sensitized and long-dialysis-time candidates is cleared from the waiting list, access for PLDs may increase. It is also important to monitor the KDPI of PLD recipients to assess the maintenance of access to high-quality kidney allografts.
Study limitations include low power for detecting preversus post-KAS differences due to small sample sizes.
To overcome the inability to estimate MWTs for newly listed patients because of a short postlisting outcome window, we used time-to-transplant analysis with lefttruncated, period-prevalent cohorts of waiting list patients. Our modeling did not explicitly account for competing risks (14, 15) , such as death on the waiting list before transplant; however, because PLDs are transplanted so quickly, deaths and other competing outcomes are exceedingly rare. Explicitly accounting for competing outcomes for other populations such as highly sensitized adults would likely only further accentuate the waiting time advantage evident for PLDs in Figure 4 .
Despite these limitations, our findings confirm that KAS effectively puts PLDs at the "top of the list" (i.e. shortest time to transplant), even if they are not literally the top priority of the allocation system delineated in OPTN policy. As intended, the current system provides quick access to high-quality organs for PLDs.
